Name: How important is the FDA approval of once-weekly dosage of Kyprolis (carfilzomib) for multiple myeloma patients?
Uploaded: 2018-11-08T12:58:27-0800
Duration: 2 min 30 s
Description: In this week’s video, Dr. Brian G.M. Durie explains the results of the A.R.R.O.W. trial, which proved the efficacy and safety of once-a-week dosing of Kyprolis for myeloma patients. BOTTOM LINE: The FDA approval of once-weekly dosing of Kyprolis is effective, more convenient for patients, and doesn’t lead to additional toxicities.

In this week’s video, Dr. Brian G.M. Durie explains the results of the A.R.R.O.W. trial, which proved the efficacy and safety of once-a-week dosing of Kyprolis for myeloma patients.

BOTTOM LINE:
The FDA approval of once-weekly dosing of Kyprolis is effective, more convenient for patients, and doesn’t lead to additional toxicities.

If you have a question that you’d like to suggest for a future episode of Ask Dr. Durie, please submit it to [email protected].

To reach the IMF InfoLine Coordinators, please call 800.452.2873 or email them at [email protected].

Image of Dr. Brian G.M. Durie Dr. Brian G.M. Durie serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.